key: cord-0072169-9rhdypts
authors: Ruaro, Barbara; Baratella, Elisa; Confalonieri, Paola; Confalonieri, Marco; Vassallo, Fabio Giuseppe; Wade, Barbara; Geri, Pietro; Pozzan, Riccardo; Caforio, Gaetano; Marrocchio, Cristina; Cova, Maria Assunta; Salton, Francesco
title: High-Resolution Computed Tomography and Lung Ultrasound in Patients with Systemic Sclerosis: Which One to Choose?
date: 2021-12-07
journal: Diagnostics (Basel)
DOI: 10.3390/diagnostics11122293
sha: 065cbea19b17966274170918bdcf3e57ba45251a
doc_id: 72169
cord_uid: 9rhdypts

Imaging plays a pivotal role in systemic sclerosis for both diagnosis management of pulmonary complications, and high-resolution computed tomography (HRCT) is the most sensitive technique for the evaluation of systemic sclerosis-associated interstitial lung disease (SSc-ILD). Indeed, several studies have demonstrated that HRCT helps radiologists and clinicians to make a correct diagnosis on the basis of recognised typical patterns for SSc-ILD. Most SSc patients affected by ILD have a non-specific interstitial pneumonia pattern (NISP) on HRCT scan, whilst a minority of cases fulfil the criteria for usual interstitial pneumonia (UIP). Moreover, several recent studies have demonstrated that lung ultrasound (LUS) is an emergent tool in SSc diagnosis and follow-up, although its role is still to be confirmed. Therefore, this article aims at evaluating the role of LUS in SSc screening, aimed at limiting the use of CT to selected cases.

Systemic sclerosis (SSc) is an autoimmune disease that affects multiple organ systems, including the lungs [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Interstitial lung disease (ILD) is a common manifestation in systemic sclerosis (SSc) and, despite continuous advances in treatment, remains the major cause of death in SSc patients [1] [2] [3] [4] . It is of utmost importance to detect ILD in its very early stages so as to be able to choose the correct treatment regimen [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Imaging plays a central role in the management of systemic sclerosis-associated interstitial lung disease (SSc-ILD), and chest high-resolution computed tomography (HRCT) is currently considered the 'gold standard' for establishing an ILD diagnosis [14] [15] [16] [17] [18] . In early-stage SSc, the most frequent HRCT pattern is nonspecific interstitial pneumonia (NSIP), with predominant ground-glass opacity (GGO) and reticular abnormality. Less frequently, a usual interstitial pneumonia (UIP) pattern is observed, characterised by honeycombing and traction bronchiectasis [14] [15] [16] [17] [18] [19] . Over time, the radiographic progression evidences the replacement of GGO with honeycombing/traction bronchiectasis and/or bronchiolectasis. The predominant SSc-ILD pattern is NSIP, based on HRTC evaluations and/or biopsy [14] [15] [16] [17] [18] [19] [20] [21] . However,

Systemic sclerosis (SSc) is a connective tissue disease characterised by immune activation, vasculopathy and fibrosis [1] [2] [3] [4] [5] [30] [31] [32] . The fibrosis and vasculopathy processes are strictly involved in the development of SSc-ILD [1] [2] [3] [4] [5] [30] [31] [32] . The damage of SSc is initiated by microvascular injury, inducing inflammation, an autoimmune response, fibroblast activation and differentiation [13, 33] . Activated myofibroblasts perform a series of functions, culminating in an excessive deposition of the extracellular matrix and the development of fibrosis, also at the lung level [33] [34] [35] [36] [37] .

The European Scleroderma Trials and Research group (EUSTAR) studied 3656 SSc patients, and plain chest radiography evidenced the presence of ILD in about 50% of the patients with the diffuse cutaneous SSc (dcSSc) and in one-third of those with limited cutaneous SSc (lcSSc), particularly in the presence of anti-DNA topoisomerase I antibodies. SSc-specific anti-U3 RNP and anti-Th/To are also associated with SSc-ILD [37] [38] [39] [40] [41] [42] [43] .

Although the clinical course of SSc-ILD varies, making diagnosis challenging, there is a high prevalence of lung involvement in patients with an early SSc. Therefore, it is fundamental to make a correct, timely diagnosis to prevent disease progression, as it has a strong impact on the prognosis [2, 3] . Indeed, despite recent advances in treatment, the survival of SSc patients is 74.9% at 5 and 62.5% at 10 years from diagnosis, and the presence of ILD has a 2.9-fold higher mortality risk [1] [2] [3] [4] . Therefore, ILD is included in the American College of Rheumatology (ACR)/European League Against Rheumatism Collaborative Initiative (EULAR) joint classification criteria so as to be able to identify SSc in individuals without skin thickening of the fingers [41] .

As it is able to detect early changes in the lungs and subclinical lung involvement, HRCT is currently the gold standard imaging technique for the evaluation of ILD, including diagnosis and prognosis [13] [14] [15] [16] .

The HRCT examination must be performed according to a standard protocol and be correctly defined when reporting the lung alterations observed, using the glossary of terms for thoracic imaging compiled by the Fleischner Society [44] [45] [46] [47] . Nonspecific interstitial pneumonia (NSIP), with a greater proportion of ground-glass opacification (GGO) and a lower proportion of reticulation, is the most frequent HRCT early-stage pattern (Figures 1 and 2) . Less frequently, a usual interstitial pneumonia (UIP) pattern, characterised by honeycombing and traction bronchiectasis, may also be present ( Figure 3 ).

Less frequently, a usual interstitial pneumonia (UIP) pattern, characterised by honeycombing and traction bronchiectasis, may also be present ( Figure 3 ). These observations are mainly based on information obtained from HRCT studies. Lung biopsy is not generally necessary as evaluation of the HRCT pattern allows for a good prediction of the underlying histology. Therefore, lung biopsies are reserved for a minority of cases, such as when the HRCT pattern is atypical, or if there is doubt as to the diagnosis, or in the presence of a complication such as cancer. Desai et al. reported on 225 SSc patients and observed that the HRCT findings in SSc closely resembled those of NSIP as they were characterised by a predominance of GGO and fine reticular opacities, although a pattern akin to UIP was occasionally seen. HRCT has also been used to study the longitudinal behaviour of lung disease in SSc [17] . Launay et al. reported on 90 patients with SSc with the predominantly minimal interstitial disease over a 5-year period [18] . They observed that about 50% of patients with GGO abnormalities at initial CT progressed to coarser fibrosis and honeycombing, whereas the remainder remained stable. Conversely, another study reported that only 15% of patients with a normal initial HRCT showed evidence of progression at 5 years [18] . When there are associated reticular abnormalities, which are a common finding in most SSc cases, short-term disease regression has been observed in only a minority of patients, and in the longer term, GGO usually progressed to overt fibrotic change [48] [49] [50] [51] [52] [53] [54] . It is rare to see a reversal of HRCT modifications, and GGO is commonly associated with irreversible disease [48] [49] [50] [51] [52] [53] [54] . Indeed, as an improvement in HRCT findings has been observed in only 5% of patients with GGO and nonfibrotic interstitial opacities, it is reasonable to presume that GGO may represent fibrosis in many SSc cases [48] [49] [50] [51] [52] [53] [54] . Over time, apart from inflammation, fibrosis is the main histologic finding, even GGO, which represents fine reticulation and is rarely reversed but rather replaced later by overt fibrotic findings, such as reticulation or honeycombing/traction bronchiectasis and/or bronchiolectasis [48] [49] [50] [51] [52] [53] [54] . However, HRTC does have some drawbacks, including the resolution limitations of CT, e.g., anatomical structures are disclosed by variations in density measured in spatial units 'voxels'), X-ray exposure of patients and a lack of longitudinal studies on CT changes in SSc patients with and without treatment [48] [49] [50] [51] [52] [53] [54] .

Several recent studies on HRCT have demonstrated that this technique is also able to make a quantification of ILD.

Goh et al. and Warrick et al. proposed various semiquantitative scoring systems to visually quantify the extent of ILD. These can provide prognostic information, e.g., limited or extensive disease and follow-up data in SSc patients with ILD [55] [56] [57] . The semiquantitative scoring systems can visually quantify the extent of ILD, with a categorical cut-off These observations are mainly based on information obtained from HRCT studies. Lung biopsy is not generally necessary as evaluation of the HRCT pattern allows for a good prediction of the underlying histology. Therefore, lung biopsies are reserved for a minority of cases, such as when the HRCT pattern is atypical, or if there is doubt as to the diagnosis, or in the presence of a complication such as cancer. Desai et al. reported on 225 SSc patients and observed that the HRCT findings in SSc closely resembled those of NSIP as they were characterised by a predominance of GGO and fine reticular opacities, although a pattern akin to UIP was occasionally seen. HRCT has also been used to study the longitudinal behaviour of lung disease in SSc [17] . Launay et al. reported on 90 patients with SSc with the predominantly minimal interstitial disease over a 5-year period [18] . They observed that about 50% of patients with GGO abnormalities at initial CT progressed to coarser fibrosis and honeycombing, whereas the remainder remained stable. Conversely, another study reported that only 15% of patients with a normal initial HRCT showed evidence of progression at 5 years [18] . When there are associated reticular abnormalities, which are a common finding in most SSc cases, short-term disease regression has been observed in only a minority of patients, and in the longer term, GGO usually progressed to overt fibrotic change [48] [49] [50] [51] [52] [53] [54] . It is rare to see a reversal of HRCT modifications, and GGO is commonly associated with irreversible disease [48] [49] [50] [51] [52] [53] [54] . Indeed, as an improvement in HRCT findings has been observed in only 5% of patients with GGO and nonfibrotic interstitial opacities, it is reasonable to presume that GGO may represent fibrosis in many SSc cases [48] [49] [50] [51] [52] [53] [54] . Over time, apart from inflammation, fibrosis is the main histologic finding, even GGO, which represents fine reticulation and is rarely reversed but rather replaced later by overt fibrotic findings, such as reticulation or honeycombing/traction bronchiectasis and/or bronchiolectasis [48] [49] [50] [51] [52] [53] [54] . However, HRTC does have some drawbacks, including the resolution limitations of CT, e.g., anatomical structures are disclosed by variations in density measured in spatial units 'voxels'), X-ray exposure of patients and a lack of longitudinal studies on CT changes in SSc patients with and without treatment [48] [49] [50] [51] [52] [53] [54] .

Several recent studies on HRCT have demonstrated that this technique is also able to make a quantification of ILD.

Goh et al. and Warrick et al. proposed various semiquantitative scoring systems to visually quantify the extent of ILD. These can provide prognostic information, e.g., limited or extensive disease and follow-up data in SSc patients with ILD [55] [56] [57] . The semiquantitative scoring systems can visually quantify the extent of ILD, with a categorical cut-off of 20% to distinguish limited and extensive parenchymal involvement with prognostic implications. More recently, the use of quantitative imaging and artificial intelligence have allowed for objective quantification of ILD through the use of dedicated software, which calculates different parameters of lung density [55] . Several studies have demonstrated the correlation between quantitative and semiquantitative ILD assessment. Yabuuchi et al. [58] observed a significant correlation between the quantitative assessment based on the PFT results and semiquantitative disease extent scores. These results were confirmed by Ninaber et al., Marten et al. and Koyama et al. [59] [60] [61] .

Salaffi et al. [62, 63] used the Warrick-score to evaluate the semiquantitative disease extent and reported an excellent correlation between quantitative and semiquantitative disease extent scores. Ariani et al. [64] reported that quantitative lung assessment (QLA) can differentiate mortality risk categories in patients with SSc. They also observed that QLA is useful in the treatment follow-up of SSc patients and the evaluation of pulmonary healing in SSc patients who had autologous stem cell transplantation [58, 65, 66] . Recently, Bocchino et al. reported that QLA values are significantly correlated with both PFTs and immune parameters (i.e., soluble cytokine receptors) [67] .

Very recently, Sambataro et al. have correlated the Quantitative Computed Tomography (QCT) score with disease activity (DA) in SSc patients [68] . The results of this study suggest that QCT can identify SSc patients with a high DA score. This may well open up a scenario of new applications as an operator-independent contribution in DA scores with a potential role for application in clinical practice [69] .

HRCT is not suitable for frequent screening of the lung parenchymal modifications due to the risks involved in the use of ionizing radiation and high costs. The utility of a lung ultrasound (LUS) in the diagnosis of ILD in very early SSc has also been described and, more recently, its potential for the detection of SSc-ILD in asymptomatic preclinical stages [70, 71] . Recent research has focused on the predictive value of LUS [72, 73] , which is promising for the application of LUS as a screening method for SSc-ILD in clinical practice. Although these are strong arguments in favour of the application of LUS in SSc, to date, there is no unanimous consensus as to the role LUS plays in the diagnosis and/or prognosis of SSc-ILD.

The main LUS signs for ILD-SSc assessment are B-lines and pleural line alterations (Figures 2 and 4) . The B-line, generally not present in the lungs of healthy subjects, is defined as a hyperechoic narrow base reverberation artefact, which extends like a laser beam up to the edge of the screen [74, 75] . B-lines are excellent markers of pulmonary interstitial involvement, whatever the etiology. However, it must not be forgotten that B-line artifacts have also been reported in patients with cardiogenic pulmonary oedema, interstitial pneumonia (e.g., due to viral infection), acute respiratory distress syndrome (ARDS) and diffuse alveolar haemorrhage [76, 77] . It should also be noted that B-line artifacts in patients diagnosed with ILD occur both in actively developing lesions (such as the finding of ground-glass in HRCT) and already existing ones (e.g., honeycombing) [78] . Convex transducers are considered to be the best for the identification of B-lines, especially for the purpose of quantification/semi-quantification [74] [75] [76] [77] [78] .

When B-lines can be identified singularly, they can be enumerated one by one. However, when they are confluent, such as in the advanced stages of ILD, it is useful to assess the percentage of hyperechoic "white" signal generated by the B-lines below the pleural line and then divide it by 10 [74, 75] . Some studies have focused on the assessment of the severity of pulmonary fibrosis based on the number of B-line artifacts [79, 80] . Indeed, the counting of B-line artifacts allowed the researchers to make a mathematical correlation with the HRCT results and the application of the Warick score [81, 82] . It was reported that the more B-line artifacts were found in each patient, the more severe the pulmonary involvement was. This, in turn, was often associated with a worse gas exchange at pulmonary function tests [83] . the more B-line artifacts were found in each patient, the more severe the pulmonary involvement was. This, in turn, was often associated with a worse gas exchange at pulmonary function tests [83] . Pleural line alterations are quite a common finding in SSc-ILD, especially in the more advanced stages of the disease, whereas only a few B-lines, with no clear irregularities of the pleural line, may be observed in initial lung involvement. These alterations are better visualized by a linear or convex probe with a focus at the level of the pleural line and, as SSc-ILD usually first develops on the posterior lung bases, the LUS examination should focus on this region [74] [75] [76] [77] [78] .

Recent publications emphasize the need to pay attention to any abnormalities within the pleural line that constitute the source of vertical artifacts [84, 85] . These abnormalities can be detected with a linear transducer that has an additional diagnostic value essential in differential diagnosis [86] . Abnormalities within the pleural line include irregular, coarse, fragmented, blurred and/or thickened pleural lines [29, 87] .

Referring to the data from the 2019 meta-analysis, which analyzed 11 studies involving 487 connective tissue diseases (CTD) patients. The total sensitivity and specificity of the LUS were 0.859 (95% confidence interval (CI) 0.812-0.898) and 0.839 (95% CI 0.782-0.886), respectively. However, most of the studies present the incidence and quantitative or semi-quantitative determination of presence and number of B-lines. The presentation of the ultrasound model of interstitial lung disease is still not precise [88] [89] [90] .

B-lines have a sensitivity of between 59% and 100% and negative predictive value between 51.7% and 100%, while pleural line alterations have a sensitivity between 74% ★ ★ ★ ★ Pleural line alterations are quite a common finding in SSc-ILD, especially in the more advanced stages of the disease, whereas only a few B-lines, with no clear irregularities of the pleural line, may be observed in initial lung involvement. These alterations are better visualized by a linear or convex probe with a focus at the level of the pleural line and, as SSc-ILD usually first develops on the posterior lung bases, the LUS examination should focus on this region [74] [75] [76] [77] [78] .

Recent publications emphasize the need to pay attention to any abnormalities within the pleural line that constitute the source of vertical artifacts [84, 85] . These abnormalities can be detected with a linear transducer that has an additional diagnostic value essential in differential diagnosis [86] . Abnormalities within the pleural line include irregular, coarse, fragmented, blurred and/or thickened pleural lines [29, 87] .

Referring to the data from the 2019 meta-analysis, which analyzed 11 studies involving 487 connective tissue diseases (CTD) patients. The total sensitivity and specificity of the LUS were 0.859 (95% confidence interval (CI) 0.812-0.898) and 0.839 (95% CI 0.782-0.886), respectively. However, most of the studies present the incidence and quantitative or semiquantitative determination of presence and number of B-lines. The presentation of the ultrasound model of interstitial lung disease is still not precise [88] [89] [90] .

B-lines have a sensitivity of between 59% and 100% and negative predictive value between 51.7% and 100%, while pleural line alterations have a sensitivity between 74% and 85%. Furthermore, B-lines have been reported to have high specificity and a positive predictive value of 59% to 99% and of 90.6% to 95.1%, respectively and pleural lines abnormalities have almost perfect specificity (99% to 100%) [53] [54] [55] 60, 70] . Furthermore, LUS is a fast technique (the examination takes, on average, 5-7 min) [88] [89] [90] . 

Several studies have reported a correlation between the frequency of pathological findings in HRCT and LUS [91] [92] [93] . Indeed, the analysis revealed strong correlations between the observation of a reticular pattern in HRCT and the presence of the irregular, coarse and fragmented pleural lines, as well as single and multiple B-line artifacts visualized at LUS. Interlobular septal thickening was most strongly correlated with the white lung. Bronchiectasis, modified by inflammation, was strongly correlated with an irregular, coarse and fragmented pleural line. Honeycombing was strongly correlated with the presence of consolidations of <5 mm, B-line artifacts forming the white lung and blurred pleural line.

A few studies have reported the correlation between B-lines and vascular damage (capillaroscopic pattern and number of digital ulcers) [12, [69] [70] [71] [72] [73] [74] . Literature data also describe a similar correlation between pleural line alterations (a "US" thickness of >3 mm or irregularities) and HRCT, probably allowing better discrimination than B-lines in ILD detection [94] [95] [96] [97] [98] . A negative correlation has been demonstrated between B-lines and pulmonary function tests (PFT) diffusing capacity of carbon monoxide (DLCO) and forced vital capacity) [91, 94, [99] [100] [101] . The potential prognostic utility of LUS was explored by Gasparini et al. [91] , who showed that basal B-lines predict DLCO change after 12 months of follow-up and by Gargani et al. [92] , who demonstrated that a higher number of B-lines is associated with worsening or the development of pulmonary involvement.

Interstitial lung disease is one of the most common complications in systemic sclerosis and one of the main causes of morbidity and mortality. High-resolution computed tomography is the mainstay for the diagnosis of ILD as it allows for its quantification. Given the exposure to ionizing radiation that the procedure entails, other methods of ILD evaluation are under study, and one of these is lung ultrasound. To date, there is evidence in favour of the use of LUS in the screening of ILD, even in the early phases of the disease and subclinical lung involvement. LUS is fast (the examination takes on average 5-7 min) and has high sensitivity and specificity. Although further prospective studies on a larger population are necessary, the current evidence indicates that thoracic ultrasound can be used during therapeutic follow-up to complete clinical evaluation as it is practical, affordable and without side effects.

The next steps for wider applicability of LUS in the assessment of SSc-ILD are technique standardization (definition of the findings to be used, protocols for image acquisition and the quantification of findings). Moreover, other 'clinical' needs should be met, such as its validation in the early stages of the disease, evaluation of the optimal timing for diagnosis and follow-up and the determination of the minimal significant detectable changes. 

The authors declare no conflict of interest.

Predictors of progression in systemic sclerosis patients with interstitial lung disease

Trends in mortality in patients with systemic sclerosis over 40 years: A systematic review and meta-analysis of cohort studies

Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts

Advances in nailfold capillaroscopic analysis in systemic sclerosis

Quantitative Alterations of Capillary Diameter Have a Predictive Value for Development of the Capillaroscopic Systemic Sclerosis Pattern

Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention

Machine Learning Application to Predict Early Lung Involvement in Scleroderma: A Feasibility Evaluation. Diagnostics 2021

Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease

Interstitial lung disease in systemic sclerosis: Where do we stand?

Detection and classification of systemic sclerosis-related interstitial lung disease: A review

Correlation between bone quality and microvascular damage in systemic sclerosis patients

The role of chest CT in deciphering interstitial lung involvement: Systemic sclerosis versus COVID-19

Interstitial lung disease in systemic sclerosis quantification of disease classification and progression with high-resolution computed tomography: An observational study

High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients

CT features of lung disease in patients with systemic sclerosis: Comparison with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia

High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis

Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis

Laser Speckle Contrast Analysis: Functional Evaluation of Microvascular Damage in Connective Tissue Diseases. Is There Evidence of Correlations with Organ Involvement, Such as Pulmonary Damage?

Systemic sclerosis: A prototypic multisystem fibrotic disorder

Ultrasound Lung Comets in Systemic Sclerosis: A Useful Tool to Detect Lung Interstitial Fibrosis

Diagnostics 2021

Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: A literature review

Ultrasound Lung Comets in Systemic Sclerosis: A Chest Sonography Hallmark of Pulmonary Interstitial Fibrosis

Use of ultrasound to diagnose and monitor interstitial lung disease in rheumatic diseases

Development and Assessment of Novel Lung Ultrasound Interpretation Criteria for the Detection of Interstitial Lung Disease in Systemic Sclerosis

Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis

Vitamin D deficiency and clinical correlations in systemic sclerosis patients: A retrospective analysis for possible future developments

Lung Ultrasound B-Lines in Interstitial Lung Disease

Digital Ulcers in Systemic Sclerosis

Is laser speckle contrast analysis (LASCA) the new kid on the block in systemic sclerosis? A systematic literature review and pilot study to evaluate reliability of LASCA to measure peripheral blood perfusion in scleroderma patients

The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients

Pathogenesis of systemic sclerosis: Recent insights of molecular and cellular mechanisms and therapeutic opportunities

Correlation between circulating fibrocytes and dermal thickness in limited cutaneous systemic sclerosis patients: A pilot study

Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: A subgroup analysis of the SENSCIS trial

Systemic sclerosis

Prediction of pulmonary complications and long-term survival in systemic sclerosis

A clinical and serologic comparison of African-American and Caucasian patients with systemic sclerosis

Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: A longitudinal EUSTAR study

classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative

The clinical relevance of autoantibodies in scleroderma

Progression of Nailfold Microvascular Damage and Antinuclear Antibody Pattern in Systemic Sclerosis

Diagnostic criteria for idiopathic pulmonary fibrosis: A Fleischner Society White Paper

Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis

Fleischner Society: Glossary of Terms for Thoracic Imaging

Interstitial lung disease in patients with antisynthetase syndrome: A retrospective case series study

Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management

Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: Pathologic-CT correlation

Significance of Ground-glass Opacity on HRCT in Long-term Follow-up of Patients With Systemic Sclerosis

Standard and pocket-size lung ultrasound devices can detect interstitial lung disease in rheumatoid arthritis patients

Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases

Lung ultrasound to assess the severity of interstitial lung disease in systemic sclerosis

Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings

Interstitial lung disease in systemic sclerosis: A simple staging system

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis. Arthritis Rheumatol

Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective

Evaluation of the extent of ground-glass opacity on high-resolution CT in patients with interstitial pneumonia associated with systemic sclerosis: Comparison between quantitative and qualitative analysis

Lung structure and function relation in systemic sclerosis: Application of lung densitometry

Ultrasound imaging for the rheumatologist XIV. Ultrasound imaging in connective tissue diseases

Computer-assisted quantification of interstitial lung disease associated with rheumatoid arthritis: Preliminary technical validation

Computer-aided quantification of interstitial lung disease from high resolution computed tomography images in systemic sclerosis: Correlation with visual reader-based score and physiologic tests

Computer-aided tomographic analysis of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). Correlation with pulmonary physiologic tests and patientcentred measures of perceived dyspnea and functional disability

Quantitative chest computed tomography is associated with two prediction models of mortality in interstitial lung disease related to systemic sclerosis

Quantitative texturebased assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide

Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment

Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis

Correlation between quantitative computed tomography and disease activity in systemic sclerosis

Quantitative analysis of pulmonary vasculature in systemic sclerosis at spirometry-gated chest CT

The use of ultrasound for assessing interstitial lung involvement in connective tissue diseases

The promising role of lung ultrasound in systemic sclerosis

Utility of a simplified ultrasound assessment to assess interstitial pulmonary fibrosis in connective tissue disorders-preliminary results

Evaluation by ultrasound Preliminary results

The comet-tail artifact: An ultrasound sign ruling out pneumothorax

High resolution computed tomography in early scleroderma lung disease

The measurement of observer agreement for categorical data

The differing patterns of subclinical pulmonary involvement in connective tissue diseases as shown by application of factor analysis

Functional impairment in fibrosing alveolitis: Relationship to reversible disease on thin section computed tomography

Subclinical interstitial lung involvement in rheumatic diseases. Correlation of high resolution computerized tomography and functional and cytologic findings

Ultrasound mapping of lung changes in idiopathic pulmonary fibrosis

Lung ultrasound B-lines and serum KL-6 correlate with the severity of idiopathic inflammatory myositis-associated interstitial lung disease

Transthoracic ultrasonography in patients with interstitial lung disease. Lung India Off

The Use of M-Mode Ultrasonography to Differentiate the Causes of B Lines

On the Physical Basis of Pulmonary Sonographic Interstitial Syndrome

Is a linear probe helpful in diagnosing diseases of pulmonary interstitial spaces?

Clinical Impact of Vertical Artifacts Changing with Frequency in Lung Ultrasound

Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis

A simplified lung ultrasound for the diagnosis of interstitial lung disease in connective tissue disease: A meta-analysis

Diagnostic accuracy of lung ultrasound for interstitial lung disease in patients with connective tissue diseases: A meta-analysis

The predictive role of lung ultrasound in progression of scleroderma interstitial lung disease

Prognostic Value of Lung Ultrasound B-Lines in Systemic Sclerosis

Ultrasound in the Assessment of Interstitial Lung Disease in Systemic Sclerosis: A Systematic Literature Review by the OMERACT Ultrasound Group

Lung ultrasound in systemic sclerosis: Correlation with high-resolution computed tomography, pulmonary function tests and clinical variables of disease

Pulmonary echography in systemic sclerosis

Sonographic assessment of interstitial lung disease in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus

Ultrasound signs of pulmonary fibrosis in systemic sclerosis as timely indicators for chest computed tomography

Pleural irregularity, a new ultrasound sign for the study of interstitial lung disease in systemic sclerosis and antisynthetase syndrome

Effectiveness of Thoracic Ultrasonography in the Evaluation of the Severity of Pulmonary Involvement in Patients with Systemic Sclerosis

Lung Ultrasonography in the Evaluation of Interstitial Lung Disease in Systemic Connective Tissue Diseases: Criteria and Severity of Pulmonary Fibrosis-Analysis of 52 Patients

Ultrasound B-lines in the evaluation of interstitial lung disease in patients with systemic sclerosis: Cut-off point definition for the presence of significant pulmonary fibrosis